A clinical pilot study for personalized risk-based breast cancer screening utilizing a polygenic risk score
PLOS One · 08.07.2026 · 21 (7) · e0345431
DOI: 10.1371/journal.pone.0345431 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 08.07.2026. Verfasst von Tone Hovda und 8 weiteren Autor:innen. Beteiligte Einrichtung: Vestre Viken Hospital Trust, Drammen, Norway. Hauptthemen laut MEDLINE: Breast Neoplasms, Early Detection of Cancer. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EEA Grants/Norway Grants.
Abstract (Originalsprache)
Background
Population-based mammographic screening is primarily age-based. However, breast cancer risk is multifactorial, and women may benefit from personalized risk-based screening. This pilot study aimed to explore the use of polygenic risk score (PRS) as a tool for risk stratification in personalized screening.
Methods
We included 80 women aged 40–49 years referred for clinical mammography. Exclusion criteria were prior breast cancer or premalignant breast disease, and previous genetic testing. After DNA collection, PRS was calculated from 2805 Single Nucleotide Polymorphisms (SNPs). Screening recommendations were based on each participant’s relative 10-year breast cancer risk estimated from PRS and compared with the 10-year risk of an average woman of the same age. Women with a self-reported family history of cancer meeting standard criteria were referred for gene panel testing for pathogenic variants in high-risk genes. A follow up questionnaire regarding participants’ experiences was distributed 6–9 months after PRS testing.
Results
Mean age was 45.2 years (SD 2.8). Mean relative 10-year breast cancer risk was 1.18 (SD 0.57). Based on PRS, 40 participants were recommended standard biennial screening 50–69 years, while 40 were advised to begin biennial screening before age 50. Among these, 7 were recommended annual mammography from when their 10-year risk reached twice that of an average 50-year-old. Twenty-one women underwent gene panel testing; no pathogenic variants in breast cancer genes were identified. Five women were advised annual mammography from 40–60 years due to family history of breast cancer, regardless of PRS. Most respondents viewed breast cancer risk assessment positively and did not report increased anxiety after testing.
Conclusions
In this pilot cohort, PRS-based risk stratification led to earlier or more intensive screening recommendations in half of the participants, while family history also influenced management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Vestre Viken Hospital Trust, Drammen, Norway.
- OÜ Antegenes, Tartu, Estonia.
- Tartu University Hospital, Tartu, Estonia.
- Estonian Health Insurance Fund, Tallin, Estonia.
- Oslo University Hospital, Oslo, Norway.
- Cancer Registry of Norway, Oslo, Norway.
ORCID-Profile: Tone Hovda, Kristine Kleivi Sahlberg
Förderung
- EEA Grants/Norway Grants
Zitieren
APA
Hovda, T., Sober, S., Padrik, P., Kruuv-Kao, K., Grindedal, E. M., Vamre, T. B. A., Eikeland, E., Hofvind, S., & Sahlberg, K. K. (2026). A clinical pilot study for personalized risk-based breast cancer screening utilizing a polygenic risk score. PLOS One, 21(7), e0345431. https://doi.org/10.1371/journal.pone.0345431
Vancouver
Hovda T, Sober S, Padrik P, Kruuv-Kao K, Grindedal EM, Vamre TBA, et al. A clinical pilot study for personalized risk-based breast cancer screening utilizing a polygenic risk score. PLOS One. 2026;21(7):e0345431. doi:10.1371/journal.pone.0345431
BibTeX
@article{Hovda2026,
author = {Hovda, Tone and Sober, Siim and Padrik, Peeter and Kruuv-Kao, Krista and Grindedal, Eli Marie and Vamre, Tone Bøe Aaman and Eikeland, Eline and Hofvind, Solveig and Sahlberg, Kristine Kleivi},
title = {A clinical pilot study for personalized risk-based breast cancer screening utilizing a polygenic risk score},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {7},
pages = {e0345431},
doi = {10.1371/journal.pone.0345431}
}
EUVIMED